Talazoparib
Talzenna · PARP inhibitor
Renally cleared; creatinine rise.
Rubraca · Ruca
PARP inhibitor · approved 2016 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A PARP inhibitor whose creatinine bump is mostly a transporter artifact, not true kidney injury.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Early reversible serum-creatinine elevation is common and partly drug-specific: rucaparib is a recognized inhibitor of renal cation transporters, and a pooled meta-analysis found markedly higher odds of creatinine rise vs placebo across the class, but grade >=3 renal events were rare (<1%). Reported rate: elevated serum creatinine in 19.7% — Pooled safety population of seven studies of rucaparib monotherapy in patients with recurrent high-grade ovarian… (Adrianto 2024, PMID 39266137).Source: Adrianto et al., Taiwan J Obstet Gynecol 2024
Onset within the first weeks of treatment.
Distilled from: “Within the first weeks of treatment.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
PARP-inhibitor class (incl. rucaparib): significantly increased serum-creatinine elevation vs placebo (pooled OR 5.04); >=grade 3 renal events <1% — reflects inhibition of tubular creatinine transport, not GFR loss PMID 42073552 (opens PubMed in a new tab)
Inhibits and traps PARP1/2/3 on DNA, producing synthetic lethality in homologous-recombination-deficient (BRCA-mutant) tumors. Used in ovarian cancer and BRCA-mutated metastatic castration-resistant prostate cancer.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Vasculature / Endothelium
Glomerular & peritubular capillaries
7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] between 30 and 89 mL/min, as estimated by the Cockcroft-Gault method) [see Clinical Pharmacology ( 12.3 )]. Rubraca has not been studied in patients with CLcr < 30 mL/min or patients on dialysis.
Kidney rows of the label's dosage tables
From the Rubraca label (Oct 2026) · DailyMed
No row of this label's 2 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 8,832 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
517 of 8,832 reports
Reported with hospitalization
1,506 of 8,832 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Rucaparib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Talzenna · PARP inhibitor
Renally cleared; creatinine rise.
Zejula · PARP inhibitor
Hypertension and creatinine rise.
Lynparza · PARP inhibitor
Benign creatinine rise via OCT2/MATE inhibition.
Vitrakvi · TRK inhibitor
Mild creatinine rise; generally well tolerated.
Rozlytrek · TRK/ROS1 TKI
Creatinine rise via reduced tubular secretion.
Tukysa · HER2 TKI
Benign creatinine rise via tubular secretion inhibition.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Rucaparib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Rucaparib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 7 clinical records among all 8 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.